Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17084074 | 1.00 | ESR1 (0.46) | ESR1LMNACYP1A2PGRCHRM2 | |
| SCHEMBL17084078 | 1.00 | ESR1 (0.46) | ESR1LMNACYP1A2PGRCHRM2 | |
| SCHEMBL12872171 | 0.84 | ESR1 (0.45) | ESR1LMNACYP1A2PGRCHRM2 | |
| SCHEMBL24875550 | 0.83 | LMNA (0.43) | ESR1LMNACYP1A2PGRCHRM2 | |
| SCHEMBL9604739 | 0.80 | TRPA1 (0.52) | ESR1LMNACYP1A2PGRCHRM2 | |
| SCHEMBL9908242 | 0.80 | TRPA1 (0.52) | ESR1LMNACYP1A2PGRCHRM2 | |
| SCHEMBL11627988 | 0.80 | TAAR1 (0.63) | SLC6A2SLC6A3AOC3TRPA1TAAR1 | |
| SCHEMBL23188100 | 0.79 | ESR1 (0.48) | ESR1LMNACYP1A2PGRCHRM2 | |
| SCHEMBL17736720 | 0.78 | ESR1 (0.79) | ESR1LMNACYP1A2PGRCHRM2 | |
| SCHEMBL4634694 | 0.77 | ESR1 (0.78) | ESR1LMNACYP1A2PGRCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225664-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230141212-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023283453-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-11274094-B2 | Substituted benzenecarboxamides as IL-17A modulators | DICE ALPHA, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AMGEN INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210355110-A1 | THYROID HORMONE RECEPTOR AGONISTS | InventisBio Co., Ltd. (CN) | 2021-11-18 | — | — | US | disclosed |
| US-20210101886-A1 | IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. | 2021-04-08 | — | — | US | disclosed |
| WO-2021055376-A1 | IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20190290647-A1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-27 | — | — | US | disclosed |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-27 | — | — | US | disclosed |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-20 | — | — | US | disclosed |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-20 | — | — | US | disclosed |
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-09-13 | — | — | US | disclosed |
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-09-13 | — | — | US | disclosed |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION | 2011-02-03 | — | — | US | disclosed |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION | 2011-02-03 | — | — | US | disclosed |
| US-20100137320-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-06-03 | — | — | US | disclosed |
| US-20100137320-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137320-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | ESR1 2738/4885LMNA 2155/4885CYP1A2 3592/4885 |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AGTR1, AGTR2, APLNR | ESR1 1529/4885LMNA 2942/4885CYP1A2 635/4885 |
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | ESR1 2873/4885LMNA 1935/4885CYP1A2 3452/4885 |
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | IL17A, IL2, IL23R | ESR1 1216/4885LMNA 3731/4885CYP1A2 188/4885 |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | ESR1 2873/4885LMNA 1935/4885CYP1A2 3452/4885 |
| US-11274094-B2 | Substituted benzenecarboxamides as IL-17A modulators | IL17A, IL23R, IL18 | ESR1 1105/4885LMNA 4170/4885CYP1A2 464/4885 |
| US-20230141212-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | IL17A, IL2, IL23R | ESR1 1216/4885LMNA 3731/4885CYP1A2 188/4885 |
| US-20210355110-A1 | THYROID HORMONE RECEPTOR AGONISTS | TSHR, THRA, TRHR | ESR1 422/4885LMNA 3230/4885CYP1A2 606/4885 |
| US-20190290647-A1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AGTR1, AGTR2, APLNR | ESR1 1529/4885LMNA 2942/4885CYP1A2 635/4885 |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | ESR1 2580/4885LMNA 2267/4885CYP1A2 3064/4885 |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | ESR1 2880/4885LMNA 1877/4885CYP1A2 3599/4885 |
| US-20210101886-A1 | IL-17A MODULATORS AND USES THEREOF | IL17A, IL2, IL36G | ESR1 2540/4885LMNA 4464/4885CYP1A2 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.